Integrating Axatilimab Into cGVHD Care: Insights From AGAVE-201
Amandeep Salhotra, MD, discusses how chronic graft-vs-host disease (cGVHD) commonly affects transplant recipients, with risk factors including HLA mismatch and peripheral blood stem cell grafts, and how new treatments like axatilimab target the monocyte-macrophage pathway to effectively treat this condition, particularly in patients with lung involvement, while ongoing clinical trials explore both improved prophylactic strategies and corticosteroid-free interventions for moderate to severe cGVHD.
EP. 1: Understanding cGVHD: From Diagnosis to Initial Therapies
May 15th 2025A panelist discusses how chronic graft-vs-host disease (cGVHD) is a common posttransplant complication with increasing incidence due to peripheral blood stem cell grafts, older patients, and more unrelated donor transplants, which can manifest in multiple organs and is typically treated with corticosteroids as first-line therapy.
Watch
EP. 2: Inside AGAVE-201: Axatilimab for Steroid-Refractory cGVHD
May 15th 2025A panelist discusses how axatilimab, a humanized IgG4 monoclonal antibody targeting CSF-1 receptors on monocytes and macrophages, showed promising results in the AGAVE-201 trial for treatment-resistant chronic graft-vs-host disease (cGVHD), with high response rates, durable responses, and tolerable adverse effects at the FDA-approved dose of 0.3 mg/kg every 2 weeks.
Watch
EP. 3: Clinical Considerations for Axatilimab Use in Steroid-Refractory cGVHD
May 27th 2025A panelist discusses how axatilimab demonstrated efficacy in a heavily pretreated patient population with predominantly severe chronic graft-vs-host disease (cGVHD) in the AGAVE-201 trial, with manageable adverse effects including infusion reactions and enzyme elevations that rarely required discontinuation of treatment.
Watch
EP. 4: Expanding the Treatment Landscape for Steroid-Refractory cGVHD Care With Axatilimab
May 27th 2025A panelist discusses how axatilimab is particularly effective for patients with bronchiolitis obliterans syndrome, showing response rates of almost 50% with 20% complete responses, and offers the advantage of reliable intravenous delivery despite logistical challenges of infusion center visits.
Watch
EP. 5: Steroid-Refractory cGVHD Care: Axatilimab in the Community Setting
June 3rd 2025A panelist discusses how community-based care coordination can be implemented for patients with chronic graft-vs-host disease (cGVHD) on axatilimab, with initial cycles administered at specialized centers followed by local infusions under community oncologist supervision, with periodic assessment visits to evaluate treatment response.
Watch
EP. 6: Future Directions for cGVHD Care
June 3rd 2025A panelist discusses how advances in chronic graft-vs-host disease (cGVHD) prevention include posttransplant cyclophosphamide showing significant reduction in moderate to severe cGVHD and the promising Precision-T trial using split-dose infusions of regulatory T cells followed by conventional T cells, both demonstrating improved cGVHD-free survival compared with standard prophylaxis.
Watch
